

D1  
C00-1  
10. **(Amended)** A method according to claim 9, wherein a library of candidate bioactive agents is added to a plurality of hematopoietic cells comprising a recombinant nucleic acid encoding a Toso cell-surface receptor.

---

11. A method according to claim 9 further comprising adding a labeling agent that will label apoptotic cells.

12. A method according to claim 11 further comprising separating apoptotic cells from non-apoptotic cells.

13. A method according to claim 11 wherein said labeling agent is annexin.

14. A method according to claim 12 wherein said separation is done by FACS.

15. A method according to claim 9 wherein said apoptotic agent is selected from the group consisting of an anti-Fas antibody, TNF- $\alpha$ , FADD, cycloheximide, PMA, ionomycin and chemotherapeutic agents.

16. A method of modulating apoptosis in a cell comprising administering to said cell an exogenous compound that binds to a Toso protein wherein said binding modulates the biological activity of said Toso protein.

---

D2  
17. **(Amended)** A method according to claim 16 wherein the binding of said exogenous compound to said Toso protein reduces or eliminates the biological activity of said Toso protein.

18. **(Amended)** A method according to claim 16 wherein the binding of said exogenous compound to said Toso protein increases the biological activity of said Toso protein.

---

D3  
26. **(New)** The method according to claim 9, wherein the hematopoietic cell is a lymphocyte.

27. **(New)** The method according to claim 26, wherein the lymphocyte is a B lymphocyte.

D3  
28. **(New)** The method according to claim 26, wherein the lymphocyte is a T lymphocyte.

29. **(New)** The method according to claim 26, wherein the hematopoietic cell is a lymphoid cell.